1: Sassine J, Siegrist EA, Shafat TF, Chemaly RF. Advances and prospect in herpesviruses infections after haematopoietic cell transplantation: closer to the finish line? Clin Microbiol Infect. 2024 Jun 28:S1198-743X(24)00300-8. doi: 10.1016/j.cmi.2024.06.020. Epub ahead of print. PMID: 38945270.
2: Normand C, Thieulent CJ, Fortier C, Sutton G, Senamaud-Beaufort C, Jourdren L, Blugeon C, Vidalain PO, Pronost S, Hue ES. A Screening Study Identified Decitabine as an Inhibitor of Equid Herpesvirus 4 That Enhances the Innate Antiviral Response. Viruses. 2024 May 8;16(5):746. doi: 10.3390/v16050746. PMID: 38793627; PMCID: PMC11125953.
3: de Vries M, Bonsmann S, Pausch J, Sumner M, Birkmann A, Zimmermann H, Kropeit D. Evaluation of the Clinical Drug-Drug Interaction Potential of Pritelivir on Transporters and CYP450 Enzymes Using a Cocktail Approach. Clin Pharmacol Drug Dev. 2024 Jul;13(7):755-769. doi: 10.1002/cpdd.1408. Epub 2024 May 16. PMID: 38752475.
4: Wang X, Patrikeeva S, Nanovskaya T, Bryant V. Development and validation of HPLC-ultraviolet method for quantitative determination of pritelivir in human placental perfusion medium. Biomed Chromatogr. 2024 Jul;38(7):e5888. doi: 10.1002/bmc.5888. Epub 2024 May 10. PMID: 38727008; PMCID: PMC11262560.
5: Gege C, Kleymann G. Replacement of sulfonamide by sulfoximine within a helicase-primase inhibitor with restricted flexibility. Bioorg Med Chem Lett. 2024 Jul 1;106:129761. doi: 10.1016/j.bmcl.2024.129761. Epub 2024 Apr 19. PMID: 38642810.
6: Bonsmann S, McCormick D, Pausch J, de Vries M, Sumner M, Birkmann A, Zimmermann H, Kropeit D. Mass Balance and Metabolite Profile after Single and Multiple Oral Doses of Pritelivir in Healthy Subjects. Clin Pharmacol Drug Dev. 2024 Apr;13(4):389-403. doi: 10.1002/cpdd.1358. Epub 2024 Jan 8. PMID: 38189209.
7: Srinivasan K, Ho DY. Case Commentary: "Salvage Treatment of Refractory HSV Oral Lesions with Pritelivir in Allogeneic Hematopoietic Cell Transplant Recipients" by Bosetti et al. Antimicrob Agents Chemother. 2023 May 17;67(5):e0027623. doi: 10.1128/aac.00276-23. Epub 2023 Apr 4. PMID: 37014226; PMCID: PMC10190666.
8: Bosetti D, Bernardi C, Maulini M, Giannotti F, Mamez AC, Masouridi-Levrat S, Chalandon Y, Neofytos D. Salvage Treatment of Refractory HSV Oral Lesions with Pritelivir in Allogeneic Hematopoietic Cell Transplant Recipients. Antimicrob Agents Chemother. 2023 Apr 18;67(4):e0173222. doi: 10.1128/aac.01732-22. Epub 2023 Mar 27. PMID: 36971558; PMCID: PMC10112206.
9: Kropeit D, Bonsmann S, von Richter O, McCormick D, Pausch J, Sumner M, Birkmann A, Zimmermann H, Rübsamen-Schaeff H. First-in-Human, Single- and Multiple-Ascending-Dose, Food-Effect, and Absolute Bioavailability Trials to Assess the Pharmacokinetics, Safety, and Tolerability of Pritelivir, a Nonnucleoside Helicase-Primase Inhibitor Against Herpes Simplex Virus in Healthy Subjects. Clin Pharmacol Drug Dev. 2023 Jul;12(7):749-760. doi: 10.1002/cpdd.1241. Epub 2023 Mar 1. PMID: 36860173.
10: Kotton BD, Kotton CN. Resistant herpes simplex virus infections - who, when, and what's new? Curr Opin Infect Dis. 2022 Dec 1;35(6):530-535. doi: 10.1097/QCO.0000000000000889. Epub 2022 Oct 7. PMID: 36206151.
11: Birkmann A, Bonsmann S, Kropeit D, Pfaff T, Rangaraju M, Sumner M, Timmler B, Zimmermann H, Buschmann H, Ruebsamen-Schaeff H. Discovery, Chemistry, and Preclinical Development of Pritelivir, a Novel Treatment Option for Acyclovir- Resistant Herpes Simplex Virus Infections. J Med Chem. 2022 Oct 27;65(20):13614-13628. doi: 10.1021/acs.jmedchem.2c00668. Epub 2022 Oct 6. PMID: 36202389; PMCID: PMC9620171.
12: Gege C, Kleymann G. Helicase-primase inhibitors from Medshine Discovery Inc. (WO2018/127207 and WO2020/007355) for the treatment of herpes simplex virus infections - structure proposal for Phaeno Therapeutics drug candidate HN0037. Expert Opin Ther Pat. 2022 Sep;32(9):933-937. doi: 10.1080/13543776.2022.2113873. Epub 2022 Aug 19. PMID: 35965439.
13: Serris A, Pouvaret A, Loiseau C, Abid H, Burrel S, Fourgeaud J, Rouzaud C, Lanternier F, Boutolleau D, Frange P. Pritelivir for recurrent aciclovir- resistant herpes simplex virus 2 infections in immunocompromised patients. J Antimicrob Chemother. 2022 Jul 28;77(8):2303-2305. doi: 10.1093/jac/dkac165. PMID: 35639560.
14: Spahn S, Riessen R, Berg CP, Malek NP, Emrich MH, Lohrengel K, Ganzenmueller T, Iftner T, Kleymann G, Hamprecht K. Comprehensive clinical and virological characterization of three cases of fulminant liver failure owing to HSV1 primary infection. Liver Int. 2022 May;42(5):1005-1011. doi: 10.1111/liv.15215. Epub 2022 Mar 7. PMID: 35230726.
15: Nandi R, Bhowmik D, Srivastava R, Prakash A, Kumar D. Discovering potential inhibitors against SARS-CoV-2 by targeting Nsp13 Helicase. J Biomol Struct Dyn. 2022;40(22):12062-12074. doi: 10.1080/07391102.2021.1970024. Epub 2021 Aug 28. PMID: 34455933.
16: Shiraki K, Yasumoto S, Toyama N, Fukuda H. Amenamevir, a Helicase-Primase Inhibitor, for the Optimal Treatment of Herpes Zoster. Viruses. 2021 Aug 5;13(8):1547. doi: 10.3390/v13081547. PMID: 34452412; PMCID: PMC8402822.
17: Schultz A, Knoll T, Urban A, Schuck H, von Briesen H, Germann A, Velten T. Novel Cost-Efficient Graphene-Based Impedance Biosensor for the Analysis of Viral Cytopathogenicity and the Effect of Antiviral Drugs. Front Bioeng Biotechnol. 2021 Jul 26;9:718889. doi: 10.3389/fbioe.2021.718889. PMID: 34381768; PMCID: PMC8350578.
18: Cannon L, Tholouli E, Ward C, Farooq H, Kingston M. Use of pritelivir in refractory aciclovir-resistant herpes simplex virus type 2. Int J STD AIDS. 2021 Sep;32(10):978-980. doi: 10.1177/09564624211006568. Epub 2021 May 4. PMID: 33947276.
19: Thieulent C, Hue ES, Sutton G, Fortier C, Dallemagne P, Zientara S, Munier- Lehmann H, Hans A, Paillot R, Vidalain PO, Pronost S. Identification of antiviral compounds against equid herpesvirus-1 using real-time cell assay screening: Efficacy of decitabine and valganciclovir alone or in combination. Antiviral Res. 2020 Nov;183:104931. doi: 10.1016/j.antiviral.2020.104931. Epub 2020 Sep 11. PMID: 32926887.
20: Ruebsamen-Schaeff H, Buschmann H. Different solid forms for optimizing route of administration of the herpes drug Pritelivir. Medchemcomm. 2019 Aug 9;10(11):1867-1870. doi: 10.1039/c9md00233b. PMID: 32346467; PMCID: PMC7161071.